ARTIST MRI (AMPA [alpha-amino-3-hydroxy-5-methylisoxazole-4- propionic acid] Receptor Antagonist Treatment in Ischemic Stroke Trial-MRI [magnetic resonance imaging]) A randomized, double-blind, placebo-controlled study to evaluate effects of YM872 [zonampanel] on lesion volume as measured by diffusion, perfusion, and FLAIR [fast fluid-attenuated inversion-recovery] MRI In patients with acute ischemic stroke

Trial Profile

ARTIST MRI (AMPA [alpha-amino-3-hydroxy-5-methylisoxazole-4- propionic acid] Receptor Antagonist Treatment in Ischemic Stroke Trial-MRI [magnetic resonance imaging]) A randomized, double-blind, placebo-controlled study to evaluate effects of YM872 [zonampanel] on lesion volume as measured by diffusion, perfusion, and FLAIR [fast fluid-attenuated inversion-recovery] MRI In patients with acute ischemic stroke

Not stated
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 May 2007

At a glance

  • Drugs Zonampanel (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top